FUTURE PLANS

See "Business — Strategies" for a detailed description of our future plans.

USE OF [REDACTED]

We estimate that the aggregate net [**REDACTED**] from the [**REDACTED**] will be approximately HK$[**REDACTED**], after deducting estimated [**REDACTED**], fees and expenses in connection with the [**REDACTED**] payable by us, and assuming that the [**REDACTED**] and the [**REDACTED**] are not exercised and an [**REDACTED**] of HK$[**REDACTED**] per Share, being the mid-point of the [**REDACTED**].

In line with our strategies, we currently intend to apply the [**REDACTED**] from the [**REDACTED**] for the following purposes:

- approximately [**REDACTED**]%, or HK$[**REDACTED**], will be used to fund the ongoing and planned clinical trials, R&D, regulatory approval preparations, CMC activities, and the anticipated commercialization of our Core Product, ifebemtinib (IN10018), in China, of which:
    - approximately [**REDACTED**]%, or HK$[**REDACTED**], will be used to fund the ongoing trials, regulatory approval preparations, and CMC activities of ifebemtinib for PROC in China. We have advanced the combination therapy with PLD to a Phase III registrational clinical trial and expect to make an NDA submission in the second half of 2026. The [**REDACTED**] will be allocated across the following activities and timeframes:
        - approximately [**REDACTED**]%, or HK$[**REDACTED**], will be used to fund the ongoing Phase III clinical trial to support the completion of patient enrollment, ongoing patient treatment and monitoring, follow-up activities and survival data collection through 2026, data monitoring committee oversight, final data analysis and clinical study reporting.
        - approximately [**REDACTED**]%, or HK$[**REDACTED**], will be used to fund regulatory preparation and NDA submission, as well as CMC activities. We expect to prepare an NDA package for submission to the NMPA in the second half of 2026, including efficacy and safety analyses, preparation of proposed product labeling, engagement with the CDE regarding the approval pathway, and preparation for regulatory inspections. To support commercial launch following potential approval in 2026, we also plan to complete process validation, manufacture initial commercial inventory, and establish commercial quality control standards and testing protocols.
    - approximately [**REDACTED**]%, or HK$[**REDACTED**], will be used to fund the ongoing clinical trial, regulatory approval preparations, and translational research of ifebemtinib for NSCLC in China. We are exploring ifebemtinib in combination with D-1553 (garsorasib), a novel KRAS G12C inhibitor, in a Phase III registrational clinical trial in China for first-line treatment of NSCLC patients with KRAS G12C mutation. We expect to complete this trial in 2027 to support an anticipated NDA submission by 2028.
    - approximately [**REDACTED**]%, or HK$[**REDACTED**], will be used to fund the ongoing and planned clinical trials, regulatory approval preparations, and translational research of ifebemtinib for CRC in China. We are studying ifebemtinib in combination with a KRAS G12C inhibitor, D-1553 (garsorasib), in KRAS G12C-mutated CRC in patients who have received at least two prior lines

of therapy in an ongoing Phase Ib/II clinical trial. We expect to advance this combination therapy to a Phase III registrational clinical trial in China in the second half of 2026. The [**REDACTED**] will be used to fund (i) the IND submission for the Phase III trial, (ii) clinical trial operations including site initiation, patient recruitment and enrollment, clinical monitoring and data management, safety oversight, investigator fees, and data monitoring, and (iii) translational research activities.

  - approximately [**REDACTED**]%, or HK$[**REDACTED**], will be used to fund the ongoing and planned clinical trials of ifebemtinib in combination with ADCs, KRAS G12D inhibitors, and other therapeutic modalities for additional solid tumor indications including gastric cancer, pancreatic cancer, and other RAS-mutated cancers in China. We have obtained IND approvals from the NMPA for Phase Ib/II clinical trials evaluating ifebemtinib in combination with ESG401 (TROP-2 ADC) and GQ1005 (HER2 ADC) for advanced solid tumors. We expect to initiate Phase II trials in the second half of 2026, enrolling patients across multiple tumor types to evaluate safety, tolerability, and preliminary efficacy. We obtained an IND approval from the NMPA in October 2025 to advance ifebemtinib in combination with a KRAS G12D inhibitor, RNK08954, for the treatment of KRAS G12D-mutated advanced solid tumors into a Phase Ib/II clinical trial in China. We initiated the Phase II portion of this trial in April 2026, with proof of concept data read-out expected in the second half of 2026. Additionally, based on preclinical findings from our translational medicine platform, we may initiate other exploratory clinical trials evaluating ifebemtinib in combinations with other targeted therapies or immunotherapies, with specific programs to be determined based on emerging preclinical data and strategic priorities.

  - approximately [**REDACTED**]%, or HK$[**REDACTED**], will be used to prepare for the anticipated commercial launch of ifebemtinib in China, for which we intend to build a dedicated commercialization team for ifebemtinib. We plan to recruit a commercial team including sales representatives covering key oncology centers and hospitals in tier-1 and tier-2 cities across China, medical science liaisons to engage with key opinion leaders, and commercial operations personnel to manage distribution and logistics.

- approximately [**REDACTED**]%, or HK$[**REDACTED**], will be used to fund R&D, regulatory approval preparations, CMC activities of our other pipeline assets, including IN10028, OMTX705, IN30758, and IN30778, of which:

  - approximately [**REDACTED**]%, or HK$[**REDACTED**], will be used to fund the clinical development of IN10028. We obtained an IND approval for IN10028 from the NMPA in March 2026 and expect to initiate the Phase I clinical trial in the first half of 2026.

  - approximately [**REDACTED**]%, or HK$[**REDACTED**], will be used to fund the clinical development of our ADC candidates, for instance, OMTX705, IN30758, and IN30778. For OMTX705, we are accelerating clinical development and seeking the optimal registration pathway and strategy to secure regulatory approval and swift market entry in China through strategic international clinical collaborations. We plan to incorporate the safety, tolerability, and pharmacokinetic data from Oncomatryx's ongoing global Phase I trial to optimize our clinical trial design in China, which may include streamlined dose escalation and refined patient selection criteria, and to initiate the Phase II clinical trial in China in 2026. We obtained an IND approval for IN30758 from the NMPA in March 2026 and expect

to initiate the Phase I clinical trial in the second half of 2026. For IN30778, we expect to complete all pre-clinical studies, and use data generated from these studies to submit an IND application in 2027.

- approximately [**REDACTED**]%, or HK$[**REDACTED**], will be used to fund our continuous pre-clinical research and development of multiple pre-clinical- and discovery-stage assets.

- approximately [**REDACTED**]%, or HK$[**REDACTED**], will be used to fund the establishment of our manufacturing capacity including facility design and construction, procurement and installation of manufacturing equipment, cleanroom build-out to meet GMP standards, and recruitment and training of manufacturing and quality control personnel. We expect to evaluate our manufacturing facility build-out schedule within one to two years following the commercial launch of ifebemtinib for PROC, taking into account product ramp-up, progress of additional indications, and the evolving competitive landscape.

- approximately [**REDACTED**]%, or HK$[**REDACTED**], will be used for working capital and other general corporate purposes.

The above allocation of the [**REDACTED**] will be adjusted on a pro rata basis in the event that the [**REDACTED**] is fixed at a higher or lower level compared to the mid-point of the estimated [**REDACTED**].

If the [**REDACTED**] is exercised in full, the [**REDACTED**] of the [**REDACTED**] will increase to approximately HK$[**REDACTED**], assuming an [**REDACTED**] of HK$[**REDACTED**] per [**REDACTED**], being the mid-point of the [**REDACTED**] and after deducting the estimated [**REDACTED**] fees and [**REDACTED**] payable by us. We intend to apply the additional [**REDACTED**] to the above purposes in the proportions stated above.

To the extent that our [**REDACTED**] are not sufficient to fund the purposes set out above, we intend to fund the balance through a variety of means, including cash generated from operations, financial support from our existing shareholders, bank loans and other borrowings.

To the extent that the [**REDACTED**] from the [**REDACTED**] are not immediately used for the purposes described above and to the extent permitted by the relevant laws and regulations, the unused [**REDACTED**] will be placed in short-term deposits with licensed banks and/or authorized institutions in Hong Kong (as defined under the Securities and Futures Ordinance) or China (as defined under the applicable laws in China).

We will issue an appropriate announcement if there is any material change to the above proposed use of [**REDACTED**].